Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer

Figure 1 Flow chart of patient inclusion. MSS: Microsatellite stable; TAS-102: Trifluridine/tipiracil.

Figure 2 Kaplan-Meier curve of original cohort (progression-free survival). TP: Targeted therapy combined with anti-programmed cell death 1 immunotherapy; TB: Bevacizumab.

Figure 3 Propensity score-matching analysis in progression-free survival. A: After propensity score-matching analysis in progression-free survival (PFS) (ratio = 4); B: After propensity score-matching analysis in PFS (ratio = 3); C: After propensity score-matching analysis in PFS (ratio = 2); D: After propensity score-matching analysis in PFS (ratio = 1); E: After inverse probability of treatment weighting analysis (PFS). TP: Targeted therapy combined with anti-programmed cell death 1 immunotherapy; TB: Bevacizumab.

Figure 4 Kaplan-Meier curve of landmark analysis in progression-free survival. A: Survival curves stratified by a 90-day landmark timepoint; B: Survival curves stratified by a 120-day landmark timepoint; C: Survival curves stratified by a 150-day landmark timepoint. TP: Targeted therapy combined with anti-programmed cell death 1 immunotherapy; TB: Bevacizumab.

Figure 5 Forest plots depict the hazard ratios and 95% confidence intervals for progression-free survival by subgroup. HR: Hazard ratio; CI: Confidence interval.